AirWare’s Brez nasal breathing aids now available at Rite Aid, independent pharmacies
SCOTTSDALE, Ariz. AirWare on Wednesday announced the availability of its Brez nasal breathing aids, a device that fits inside the nose that reduces snoring and improves sleep quality, nationally through Rite Aid.
Brez, available in three sizes, inserts easily into the nose and gently lifts, expands and supports the interior walls of the nasal passages to reduce the resistance of airflow. Brez has been reviewed and categorized as a Class I exempted medical device, based on Food and Drug Administration definitions, for marketing as an over-the-counter treatment to help relieve symptoms for multiple conditions related to impaired breathing, such as snoring, congestion due to the common cold or allergies and deviated septum.
In addition to Rite Aid, the product is available at several independent pharmacies nationwide.
“We’re pleased to begin our product launch with Rite Aid and independent pharmacies as our partners.” stated Mindi Osborn, AirWare president and CEO. “Brez is different than anything else on the market today because it effectively conforms to the user’s anatomy to provide a proactive, non-pharmacological solution to snoring.”
Data from an independent clinical study involving 26 snorers (12 men and 14 women) with snoring (non-apneic) bed partners showed that those who used Brez experienced a 52% decrease in snoring events from an average of 1,247 to 654. Snorers who used the device had only a 22.4% likelihood of persistent snoring and disturbing their bed partner’s sleep compared with their pre-treatment scores of 100%.
“I am impressed by the independent clinical data showing Brez usage resulted in a significant reduction of more than 50% of snoring events. Equally interesting, 88% of bed partners reported improved sleep quality when the product was used by the snorer,” stated George Gwinn, clinical investigator for PsyPharma Global, and allergy and pulmonary specialist. “Each day, pharmacists nationwide serve as front-line healthcare providers to help consumers deal with issues such as snoring. Based on these data, it appears that Brez may be an innovative solution that pharmacists can recommend.”
McNeil warms Chicago commuters with Tylenol campaign
CHICAGO McNeil Consumer Healthcare has shifted gears in its on-the-street promotion of Tylenol Warming Liquids by heating 10 bus shelters in downtown Chicago. The shelters will be heated through March 8, McNeil stated.
“Experiential marketing, such as heated bus shelters, has become an increasingly popular means of connecting with consumers and providing them with a relevant sensation instead of just a message,” McNeil stated in a press release Monday. “In addition to the heated bus shelters, Tylenol Warming Liquids advertisements at 10 other locations in Chicago will feature heated panels.”
Earlier this winter, McNeil staged Tylenol Warming Liquids taxis in front of select CVS/pharmacy locations in Boston, New York, Philadelphia and Washington. As part of that promotion, taxi services within city limits were offered free of charge.
FDA issues warning for ALR dietary supplement
ROCKVILLE, Md. The Food and Drug Administration Tuesday afternoon warned consumers not to take Venom HYPERDRIVE 3.0, a product sold as a dietary supplement and containing sibutramine. Sibutramine, a controlled substance with risks for abuse or addiction, is a potent drug that poses potential safety risks, the agency stated.
“Sibutramine is the active ingredient in an FDA-approved prescription drug used as an appetite suppressant for weight loss,” stated Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research. “But when present in a dietary supplement, it may harm unsuspecting consumers because sibutramine can substantially increase blood pressure and heart rate … and may present a significant risk for people with a history of heart disease, heart failure, irregular heartbeats or stroke.”
Venom HYPERDRIVE 3.0 is marketed by Applied Lifescience Research. On Dec. 24, ALR initiated a recall of all lots of Venom HYPERDRIVE 3.0 after the FDA laboratory analysis showed samples of the product contained undeclared sibutramine. Although ALR Industries claims on its Web site that only “trace amounts” of sibutramine were found in this product, the FDA laboratory tests showed that Venom HYPERDRIVE 3.0 contains a significant amount of sibutramine per dosage unit.
The product was sold via distributors and in retail stores nationwide, as well as in Canada, Poland, Sweden, Hungary, South Africa, the Netherlands, Australia, France and the United Kingdom. The product was packaged in red plastic bottles containing 90 capsules each with the UPC# 094922534743.
Consumers who have this product should stop taking it immediately and contact their healthcare professional if they have experienced any adverse effects.